Cefoperazone Sodium

Cefoperazone sodium interferes with bacterial cell wall synthesis by binding to penicillin-binding proteins, thereby inhibiting transpeptidation and causing osmotic lysis of susceptible bacteria. A cefoperazone sodium-impregnated polycaprolactone composite implant was fabricated using a melt molding technique for local treatment of osteomyelitis. The implant produced significant zones of inhibition against Staphylococcus aureus in in vitro antibacterial testing. Drug release from the polycaprolactone matrix occurred in a sustained manner over an extended period. Scanning electron microscopy revealed distinct surface morphology changes of the implant before and after drug release. The composite implant maintained antibacterial activity for up to four weeks, indicating its potential for local delivery in bone infection treatment without requiring surgical removal after therapy completion.

Fig. 1 Cefoperazone Sodium impregnated calcium sulphatepolycaprolactone composite pellets. (Anand A.; et al. 2009)

A cefoperazone sodium liposomal formulation was developed using a Quality by Design approach with DPPC and cholesterol via thin film hydration for pulmonary delivery to combat Pseudomonas aeruginosa biofilm in cystic fibrosis. The optimized liposomal formulation exhibited an IC50 value of 0.42 μg/ml against biofilm formation, half that of free cefoperazone sodium. Fifty percent biofilm inhibition and eradication were achieved at approximately 1 μg/ml. The liposomes reduced cell surface hydrophobicity to 50 percent and decreased the extracellular polymeric substance component of P.aeruginosa biofilm to 17 percent. Scanning electron microscopy confirmed biofilm disintegration following liposome treatment.

Fig. 2 SEM analysis of liposomal formulation against P. aeruginosa biofilm (A) Control (B) MIC. (Ghodake V.; et al. 2020)